Drug Type CAR-T |
Synonyms- |
Target |
Action inhibitors |
Mechanism CLEC4K inhibitors(CD207 molecule inhibitors), T lymphocyte replacements |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization- |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhasePendingPhase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Refractory Langerhans Cell Histiocytosis | Phase 1 | China | 01 Oct 2022 |